The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Risk-adapted treatment of ET & PV
John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, talks on risk-adapted therapy in essential thrombocythemia (ET) and polycythemia vera (PV), discussing its purpose and how risk is determined, and also comments on emerging data on ropeginterferon alfa-2a and ropeginterferon alfa-2b. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Roche, BMS, Celgene, CTI Bio, Merck, PharmaEssentia, Abbvie, Kartos, Geron and consulting fees from Incyte, Celgene, BMS, Constellation, CTI Bio, Geron, Abbvie, Kartos, Novartis, Roche, Imago, Karyopharm, Galecto and PharmaEssentia.
